195 related articles for article (PubMed ID: 29155876)
1. Docking analysis and the possibility of prediction efficacy for an anti-IL-13 biopharmaceutical treatment with tralokinumab and lebrikizumab for bronchial asthma.
Nakamura Y; Sugano A; Ohta M; Takaoka Y
PLoS One; 2017; 12(11):e0188407. PubMed ID: 29155876
[TBL] [Abstract][Full Text] [Related]
2. A randomized, placebo-controlled trial evaluating effects of lebrikizumab on airway eosinophilic inflammation and remodelling in uncontrolled asthma (CLAVIER).
Austin CD; Gonzalez Edick M; Ferrando RE; Solon M; Baca M; Mesh K; Bradding P; Gauvreau GM; Sumino K; FitzGerald JM; Israel E; Bjermer L; Bourdin A; Arron JR; Choy DF; Olsson JK; Abreu F; Howard M; Wong K; Cai F; Peng K; Putnam WS; Holweg CTJ; Matthews JG; Kraft M; Woodruff PG;
Clin Exp Allergy; 2020 Dec; 50(12):1342-1351. PubMed ID: 32909660
[TBL] [Abstract][Full Text] [Related]
3. Lebrikizumab for the treatment of asthma.
Antoniu SA
Expert Opin Investig Drugs; 2016 Oct; 25(10):1239-49. PubMed ID: 27554950
[TBL] [Abstract][Full Text] [Related]
4. The effects of lebrikizumab in patients with mild asthma following whole lung allergen challenge.
Scheerens H; Arron JR; Zheng Y; Putnam WS; Erickson RW; Choy DF; Harris JM; Lee J; Jarjour NN; Matthews JG
Clin Exp Allergy; 2014 Jan; 44(1):38-46. PubMed ID: 24131304
[TBL] [Abstract][Full Text] [Related]
5. Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids.
Noonan M; Korenblat P; Mosesova S; Scheerens H; Arron JR; Zheng Y; Putnam WS; Parsey MV; Bohen SP; Matthews JG
J Allergy Clin Immunol; 2013 Sep; 132(3):567-574.e12. PubMed ID: 23726041
[TBL] [Abstract][Full Text] [Related]
6. A meta-analysis of anti-interleukin-13 monoclonal antibodies for uncontrolled asthma.
Li H; Wang K; Huang H; Cheng W; Liu X
PLoS One; 2019; 14(1):e0211790. PubMed ID: 30703143
[TBL] [Abstract][Full Text] [Related]
7. A Critical Evaluation of Anti-IL-13 and Anti-IL-4 Strategies in Severe Asthma.
Bagnasco D; Ferrando M; Varricchi G; Passalacqua G; Canonica GW
Int Arch Allergy Immunol; 2016; 170(2):122-31. PubMed ID: 27637004
[TBL] [Abstract][Full Text] [Related]
8. Structural basis of signaling blockade by anti-IL-13 antibody Lebrikizumab.
Ultsch M; Bevers J; Nakamura G; Vandlen R; Kelley RF; Wu LC; Eigenbrot C
J Mol Biol; 2013 Apr; 425(8):1330-9. PubMed ID: 23357170
[TBL] [Abstract][Full Text] [Related]
9. Role of periostin, FENO, IL-13, lebrikzumab, other IL-13 antagonist and dual IL-4/IL-13 antagonist in asthma.
Agrawal S; Townley RG
Expert Opin Biol Ther; 2014 Feb; 14(2):165-81. PubMed ID: 24283478
[TBL] [Abstract][Full Text] [Related]
10. Effect of genetic variation of IL-13 on airway remodeling in bronchial asthma.
Nagashima H; Nakamura Y; Kanno H; Sawai T; Inoue H; Yamauchi K
Allergol Int; 2011 Sep; 60(3):291-8. PubMed ID: 21430433
[TBL] [Abstract][Full Text] [Related]
11. Investigational anti IL-13 asthma treatments: a 2023 update.
Matera MG; Ora J; Calzetta L; Rogliani P; Cazzola M
Expert Opin Investig Drugs; 2023 May; 32(5):373-386. PubMed ID: 37194672
[TBL] [Abstract][Full Text] [Related]
12. A Mathematical Modeling Approach to Understanding the Effect of Anti-Interleukin Therapy on Eosinophils.
Karelina T; Voronova V; Demin O; Colice G; Agoram BM
CPT Pharmacometrics Syst Pharmacol; 2016 Nov; 5(11):608-616. PubMed ID: 27885827
[TBL] [Abstract][Full Text] [Related]
13. The Safety and Efficacy of Anti-IL-13 Treatment with Tralokinumab (CAT-354) in Moderate to Severe Asthma: A Systematic Review and Meta-Analysis.
Zhang Y; Cheng J; Li Y; He R; Pan P; Su X; Hu C
J Allergy Clin Immunol Pract; 2019; 7(8):2661-2671.e3. PubMed ID: 31152798
[TBL] [Abstract][Full Text] [Related]
14. Structural Characterisation Reveals Mechanism of IL-13-Neutralising Monoclonal Antibody Tralokinumab as Inhibition of Binding to IL-13Rα1 and IL-13Rα2.
Popovic B; Breed J; Rees DG; Gardener MJ; Vinall LM; Kemp B; Spooner J; Keen J; Minter R; Uddin F; Colice G; Wilkinson T; Vaughan T; May RD
J Mol Biol; 2017 Jan; 429(2):208-219. PubMed ID: 27956146
[TBL] [Abstract][Full Text] [Related]
15. Lebrikizumab treatment in adults with asthma.
Corren J; Lemanske RF; Hanania NA; Korenblat PE; Parsey MV; Arron JR; Harris JM; Scheerens H; Wu LC; Su Z; Mosesova S; Eisner MD; Bohen SP; Matthews JG
N Engl J Med; 2011 Sep; 365(12):1088-98. PubMed ID: 21812663
[TBL] [Abstract][Full Text] [Related]
16. Tralokinumab for the treatment of severe, uncontrolled asthma: the ATMOSPHERE clinical development program.
Panettieri RA; Wang M; Braddock M; Bowen K; Colice G
Immunotherapy; 2018 Mar; 10(6):473-490. PubMed ID: 29536781
[TBL] [Abstract][Full Text] [Related]
17. Comparative Efficacy of Anti IL-4, IL-5 and IL-13 Drugs for Treatment of Eosinophilic Asthma: A Network Meta-analysis.
Iftikhar IH; Schimmel M; Bender W; Swenson C; Amrol D
Lung; 2018 Oct; 196(5):517-530. PubMed ID: 30167841
[TBL] [Abstract][Full Text] [Related]
18. The Intriguing Role of Interleukin 13 in the Pathophysiology of Asthma.
Marone G; Granata F; Pucino V; Pecoraro A; Heffler E; Loffredo S; Scadding GW; Varricchi G
Front Pharmacol; 2019; 10():1387. PubMed ID: 31866859
[TBL] [Abstract][Full Text] [Related]
19. The tralokinumab story: Nothing is ever simple.
Apter AJ
J Allergy Clin Immunol; 2019 Apr; 143(4):1336-1338. PubMed ID: 30659852
[No Abstract] [Full Text] [Related]
20. Monoclonal antibodies for the treatment of refractory asthma.
Hambly N; Nair P
Curr Opin Pulm Med; 2014 Jan; 20(1):87-94. PubMed ID: 24275927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
